financetom
Business
financetom
/
Business
/
Zebra Technologies' Q2 Non-GAAP Earnings, Net Sales Increase; 2025 Outlook Updated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Zebra Technologies' Q2 Non-GAAP Earnings, Net Sales Increase; 2025 Outlook Updated
Aug 5, 2025 4:14 AM

06:57 AM EDT, 08/05/2025 (MT Newswires) -- Zebra Technologies ( ZBRA ) reported Q2 non-GAAP earnings Tuesday of $3.61 per diluted share, up from $3.18 a year earlier.

Analysts polled by FactSet expected $3.34.

Net sales for the quarter ended June 28 were $1.29 billion, compared with $1.22 billion a year earlier.

Analysts polled by FactSet expected $1.29 billion.

The company said it expects Q3 non-GAAP earnings of $3.60 to $3.80 per share and 2% to 6% in sales growth. Analysts polled by FactSet expect $3.41 in adjusted earnings per share on revenue of $1.30 billion.

Zebra Technologies ( ZBRA ) said it now expects 2025 non-GAAP earnings of $15.25 to $15.75 per share, from the previous range of $13.75 to $14.75. Analysts polled by FactSet expect $14.65.

The company also updated its 2025 sales growth outlook to between 5% and 7%, from the previous range of 3% to 7%. Analysts polled by FactSet expect $5.28 billion.

Shares of Zebra Technologies ( ZBRA ) were up more than 8% in recent premarket activity Tuesday.

Price: 371.08, Change: +29.72, Percent Change: +8.71

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biocon-Serum deal: Won't raise stake for now but alliance not limited to Covid vaccines, says Adar Poonawalla
Biocon-Serum deal: Won't raise stake for now but alliance not limited to Covid vaccines, says Adar Poonawalla
Apr 25, 2023
Serum Institute of India CEO Adar Poonawalla says the company has a 15-year horizon on the vaccine deal with Biocon Biologics.
ICICI Lombard remains cautious on private car insurance segment, says MD
ICICI Lombard remains cautious on private car insurance segment, says MD
Apr 25, 2023
Bhargav Dasgupta, the Managing Director and CEO of ICICI Lombard, one of India's leading general insurance companies believes that ease of doing business has helped the company launch new products and expand its reach in the market. However, he remains cautious on the motor segment, particularly the private car segment.
ABB global ups 2023 growth forecast and predicts strong double-digit revenue growth for second quarter
ABB global ups 2023 growth forecast and predicts strong double-digit revenue growth for second quarter
Apr 25, 2023
The leading global capital goods company ABB has revised its 2023 guidance upwards from 5 percent to nearly 10 percent. They have projected strong growth for the next quarter, expecting double-digit comparable revenue growth, following a calendar year.
Ami Organics management explains semiconductor biz foray with Baba Chemicals acquisition
Ami Organics management explains semiconductor biz foray with Baba Chemicals acquisition
Apr 25, 2023
The acquisition of Baba Fine Chemicals by Ami Organics presents a significant growth opportunity for the company. With the semiconductor industry's high barriers to entry, the acquisition provides Ami Organics with a strong foothold in this market. The company can leverage Baba Chemicals' expertise in the semiconductor industry to target new markets and expand its business.
Copyright 2023-2026 - www.financetom.com All Rights Reserved